Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
CrossRef Machine learning-based model for predicting metabolic dysfunction-associated steatotic liver disease using non-invasive parameters in young adults Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Young Hoon Youn, Su Jung Baik, Hye Sun Lee, Hyun Wook Chae Frontiers in Endocrinology .2025;[Epub] CrossRef Soft drink consumption and liver fibrosis in type 2 diabetes Arianna Ferro, Martina Bollati, Gian Paolo Caviglia, Angelo Armandi, Stefania Bellini, Selene Limoncelli, Giulio Mengozzi, Federica Barutta, Fabio Broglio, Guglielmo Beccuti, Elisabetta Bugianesi, Marilena Durazzo, Gabriella Gruden Frontiers in Nutrition .2025;[Epub] CrossRef Artificial intelligence applications for managing metabolic dysfunction-associated steatotic liver disease: Current status and future prospects Jian-Jun Lou, Jing Zeng World Journal of Gastroenterology .2025;[Epub] CrossRef Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus Virginia Markoutsaki, Georgios Dimakopoulos, Emmanouil Sinakos, Kalliopi Kotsa, Theocharis Koufakis Hormones .2025;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease and risk of heart failure: a nationwide cohort study Chan Kyeol Kim, Sangyong Jo, Kyupin Ha, Bongjo Kim, Hyeon Ji Kim, Sang Yi Moon, Byoung-Gwon Kim, Kyungil Park, Jong Sung Park, Young Rak Cho, Tae-Ho Park, Kyunghee Lim, Minkook Son Heart .2025
When considering these factors, its important to recognize that health care systems play a key role in supporting access, monitoring, and data collection for patients
This showed that semaglutide 7.2 mg led to a mean weight loss of 18.7%, outperforming the 2.4 mg dose (15.6%) at 72 weeks
That means youll always have expert support, answers to your questions, and a plan thats tailored to you
How can primary care doctors at Chandler help care for me
